Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

Inclusion criteria

• Between 19 aged and 45 aged in healthy male adult
• Over 50 kg, BMI between 18.0-29.0 kg/m2
• Subjects in good health as determined by physical exams and medical examinations. No congenital or chronic diseases and no abnormal signs determined by medical examinations.
• Not abnormal or not clinically significant lab values.
• Subjects who signed informed consent form with good understandings after explanations by investigators.

Exclusion criteria

• No history or presence of clinically significant diseases.
• Subjects showing adverse reaction to investigational product
• Genetic problems in galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
• History of myopathy
• Subjects with abnormal lab values at least one below 1) AST or ALT>2 fold of upper normal limit 2) Total bilirubin>2 fold of upper normal limit 3) CK>2 fold of upper normal limit 4) Estimated Glomerular filtration rate<60mL/min/1.73m2
• Drink over 21 units/week (1 unit= 10g=12.5mL of pure alcohol) or unable to stop drinking during clinical trials
• Smoke over 10 cigarettes per day or unable to stop smoking
• Subjects who previously participated in other clinical trials within 90 days
• Subjects who donated whole blood within 60 days or donated component blood within 30 days or received blood transfusion within 30 days
• Subjects who took any prescribed medications or oriental medicines within 14 days, or took any pharmacy medicines within 10 days.
• Taking medications which induce or block medication metabolism
• History of drug abuse
• Subjects who took any prescribed medications or oriental medicines within 14 days, or took any pharmacy medicines within 7 days.
• Disagree to contraception
• Subjects who are in any conditions impossible participating in the clinical trials